Please login to the form below

Zealand Pharma

This page shows the latest Zealand Pharma news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

therapies. Boehringer is a diabetes specialist and already has a dual GLP-1 and glucagon agonist, partnered with Zealand Pharma, in phase 1b testing. ... later this year, as well as a drug candidates for the disease covered by its recently expanded $201m

Latest news

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

The FDA has asked for more information on Sanofi and Zealand Pharma's IGlarLixi combination drug for diabetes, giving a rival drug from Novo Nordisk a chance to be first to
Sanofi uses priority review voucher for diabetes combo

The French pharma group paid $245m for the voucher - which cuts four months of the FDA's usual review time - in a deal with Retrophin earlier this year. ... Lixisenatide is a once-daily GLP-1 agonist that was invented by Zealand Pharma and has been sold
Boehringer switches diabetes candidate in Zealand collaboration

Zealand Pharma said potential choices include medicines that require once-weekly dosing, something that could give it an edge over the current leading GLP-1 agonist, Novo Nordisk's Victoza (liraglutide), ... Zealand has existing interests in the field of
Sanofi receives EU approvals for diabetes and cancer drugs

Lyxumia's approval is good news too for the drug's inventors Zealand Pharma who signed a deal with Sanofi to further develop the drug. ... Zealand also said it is eligible to receive remaining development, regulatory and sales milestone payments of up to
Hybrigenics appoints Dr Alain Munoz

As well as his position at Hybrigenics, Dr Munoz is also a board member of several biotechnology companies including Novagali Pharma and Zealand Pharma.

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.
Deal Watch table for July 2014

For an indepth analysis of these deals, read'Pharma deals during July 2014'. ... 635. Zealand Pharma/ Boehringer Ingelheim. R&D collaboration. Peptide discovery collaboration with cardio-metabolic focus.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

David Horn Solomon takes the helm of Akari Therapeutics

David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by ... Sanofi.”. His other roles have included CEO at Bionor Pharma
Glythera appoints Dr Mike Owen

Owen is also currently a director of Avacata plc, Blink Biomedical SAS, GammDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S. ... pipeline and building strategic partnerships with large pharma.”.
Bionor names executive management team additions

He has extensive experience as head of operation in public and private research intensive organisations and most recently served as director and general counsel to the management at Zealand Pharma. ... Rolstead has over 15 years of experience and has
Zealand announces management changes

Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm. . ... The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and
Zealand's Arvind Hundal steps down as chief business officer

She leaves after five years with the Danish biotech company. Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities. . ... served as a member of AstraZeneca's strategic planning business development organisation

More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Senior Medical Writer: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Account Director, Medical Education: Salary TBC

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The 2019 CPhI Pharma Index Report: Examining this year’s industry performance...
Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...